The TruSight Oncology 500 portfolio enables in-house, pan-cancer comprehensive genomic profiling (CGP) for solid tumors from either blood or tissue biopsy samples.
The TruSight Oncology 500 portfolio enables in-house, pan-cancer comprehensive genomic profiling (CGP) for solid tumors from either blood or tissue biopsy samples.
The TruSight Oncology 500 portfolio enables in-house, pan-cancer comprehensive genomic profiling (CGP) for solid tumors from either blood or tissue biopsy samples.
The TruSight Oncology 500 portfolio enables in-house, pan-cancer comprehensive genomic profiling (CGP) for solid tumors from either blood or tissue biopsy samples.